Figure 1.

Potential therapeutic targets in ATRT. Studying the effects of the reintroduction of INI1 as well as the effects of its loss has led to the identification of multiple potential therapeutic targets. INI1 loss leads to increased cyclin D1 which propagates the cell through the G1-S checkpoint. HDAC inhibitors as well as Vitamin A analogs such as retinoids and rexinoids have been shown to inhibit cyclin D1. Aurora A signaling has also been shown to be important in ATRT and multiple inhibitors of Aurora kinase signaling are available. IGF-IR signaling may also play a role in ATRT and inhibitors are available for testing.